{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-034678","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.054375+00:00","generated_at":"2026-06-04T09:55:47.143092+00:00","sec_items":["2.02","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ARS Pharma to submit CRL response in early Q2 2024; Q4 net loss $7.2M, cash $228.4M","bullets":["CRL response for neffy (epinephrine nasal spray) to be submitted early Q2 2024; FDA action and potential launch expected H2 2024.","Phase 2 urticaria trial met primary endpoints with rapid symptom control; outpatient study planned later in 2024.","Cash, equivalents and short-term investments $228.4M as of Dec 31, 2023; runway at least three years.","Net loss $7.2M in Q4, $54.4M full year 2023; R&D costs $3.4M in Q4, G&A $6.8M.","EMA MAA decision for neffy expected mid-2024; new U.S. patent issued covering intranasal epinephrine methods."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-034678","json":"https://secwatch.observer/filing/0000950170-24-034678.json","markdown":"https://secwatch.observer/filing/0000950170-24-034678.md","text":"https://secwatch.observer/filing/0000950170-24-034678.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000095017024034678/0000950170-24-034678-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000095017024034678/spry-20240321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:55:47.143092+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}